Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Takeda Pharmaceutical will inject eight drug candidates into a new biotech venture, Scohia Pharma. Innovation Network Corp. of Japan, a venture capital fund partly financed by the Japanese government, will own about 70% of the venture; the rest will be held by Takeda and its subsidiary Medipal Holdings. The drug candidates are in the renal, metabolic, and cardiovascular areas. The partners expect the spin-off to conduct research more efficiently while benefiting from Takeda scientists’ input.
This article has been sent to the following recipient: